Sphingolipids in Alzheimer's disease, how can we target them?
Altered levels of sphingolipids and their metabolites in the brain, and the related downstream effects on neuronal homeostasis and the immune system, provide a framework for understanding mechanisms in neurodegenerative disorders and for developing new intervention strategies. In this review we will discuss: the metabolites of sphingolipids that function as second messengers; and functional aberrations of the pathway resulting in Alzheimer's disease (AD) pathophysiology. Focusing on the central product of the sphingolipid pathway ceramide, we describ approaches to pharmacologically decrease ceramide levels in the brain and we argue on how the sphingolipid pathway may represent a new framework for developing novel intervention strategies in AD. We also highlight the possible use of clinical and non-clinical drugs to modulate the sphingolipid pathway and sphingolipid-related biological cascades.
|Keywords||Alzheimer's disease, Blood brain barrier (BBB), Ceramide, Fingolimod (FTY720), GW4869, Sphingomyelin (SM), Sphingosine-1-phosphate (S1P), Tricyclic dibenzoazepines (TCA)|
|Persistent URL||dx.doi.org/10.1016/j.addr.2019.12.003, hdl.handle.net/1765/124161|
|Series||VSNU Open Access deal|
|Journal||Advanced Drug Delivery Reviews|
|Note||corresponding author at University of Maastricht|
Crivelli, S.M. (Simone M.), Giovagnoni, C. (Caterina), Visseren, L. (Lars), Scheithauer, A.-L. (Anna-Lena), de Wit, N. (Nienke), den Hoedt, S. (Sandra), … Martínez-Martínez, P. (2020). Sphingolipids in Alzheimer's disease, how can we target them?. Advanced Drug Delivery Reviews. doi:10.1016/j.addr.2019.12.003